We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Hormone Replacement Therapy Causes No Excess Cardiovascular Risk

By HospiMedica staff writers
Posted on 21 Jan 2008
A new study shows that hormone replacement therapy (HRT) in women in early menopause may have no increased cardiovascular risk from the therapy, but could even show future benefit. More...


Researchers of the American Association of Clinical Endocrinologists (AACE, Jacksonville, FL, USA) conducted a meta-analysis of 23 trials that compared results of HRT in women younger than 60, or less than 10 years since menopause. Studies included the Women's Health Initiative (WHI), The Heart and Estrogen-Progestin Replacement Study (HERS), and the Postmenopausal Estrogen-Progestin Interventions study (PEPI). The study results showed that when re-evaluating the studies to permit an analysis of cardiovascular disease based on age, the studies showed that after a three-year period, there was no difference in the incidence of cardiovascular disease between the HRT group and the placebo group. The study results were issued in a press release by the AACE on January 2, 2008.

"We think the data offer some reassurance to women close to the menopause, with the suggestion that estrogen supplementation may even protect against heart disease in these younger women,” said co-author Rhoda Cobin, M.D., of the Mount Sinai School of Medicine (New York, NY, USA). "And even if it is not protective, it doesn't appear to be harmful so can probably be used safely to treat menopausal symptoms. There does appear to be a window of opportunity for use of estrogen.”

"This is an important and meaningful analysis for women who can benefit from hormone replacement therapy,” said Richard Hellman, M.D., president of the AACE. "Since the WHI was published in 2002, there has been much debate over the risk to reward ratio with this treatment option. Patient safety must always be our primary objective. We can now say with good confidence that this therapy is very safe for women under 60, or who have recently experienced menopause”.

The AACE recommends that each patient be evaluated by her doctor for the severity of her symptoms, age, and specific risk factors that might impact the efficacy of HRT. Non-hormonal therapies should be offered to those women who decline hormonal therapy.


Related Links:
American Association of Clinical Endocrinologists

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.